Published in J Transl Med on June 17, 2010
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J (1997) 5.70
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 4.10
The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci (2006) 3.62
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. Biochemistry (2008) 2.18
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol (2000) 1.85
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene (2007) 1.33
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol (2000) 1.32
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem (2004) 1.30
Molecular chaperone function of mammalian Hsp70 and Hsp40--a review. Int J Hyperthermia (2000) 1.27
A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Virology (1998) 1.12
Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells. Cancer Res (2004) 1.03
Human tumorous imaginal disc 1 (TID1) associates with Trk receptor tyrosine kinases and regulates neurite outgrowth in nnr5-TrkA cells. J Biol Chem (2005) 1.00
Tumor suppression in Drosophila is causally related to the function of the lethal(2) tumorous imaginal discs gene, a dnaJ homolog. Dev Genet (1995) 0.98
hTid-1, a human DnaJ protein, modulates the interferon signaling pathway. J Biol Chem (2001) 0.97
The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans Am Clin Climatol Assoc (2003) 0.95
HTLV-1 Tax-associated hTid-1, a human DnaJ protein, is a repressor of Ikappa B kinase beta subunit. J Biol Chem (2002) 0.95
Human T cell leukemia virus type 1 Tax associates with a molecular chaperone complex containing hTid-1 and Hsp70. Curr Biol (2001) 0.94
Tid-1 interacts with the von Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha. Cancer Res (2005) 0.94
Negative regulation of receptor tyrosine kinase signals. FEBS Lett (2001) 0.93
Genomic organization and expression of the human tumorous imaginal disc (TID1) gene. Gene (2001) 0.92
Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8. Cancer Res (2005) 0.91
Understanding human cancer using Drosophila: Tid47, a cytosolic product of the DnaJ-like tumor suppressor gene l2Tid, is a novel molecular partner of patched related to skin cancer. J Biol Chem (2003) 0.87
Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli. Oncogene (2004) 0.85
Htid-1, the human homolog of the Drosophila melanogaster l(2)tid tumor suppressor, defines a novel physiological role of APC. Cell Signal (2007) 0.81
Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med (2008) 0.80
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage (2005) 3.48
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) (2006) 2.23
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) (2007) 1.49
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol (2012) 1.25
Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues. J Cell Physiol (2008) 1.25
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene (2011) 1.14
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res (2008) 1.08
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One (2010) 0.98
A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene (2002) 0.97
Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophr Res (2008) 0.97
Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology (2012) 0.94
Chorea in systemic lupus erythematosus. J Clin Rheumatol (2011) 0.90
Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol (2008) 0.89
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res (2011) 0.87
Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res (2005) 0.85
Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. Int J Cancer (2006) 0.85
Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity. Proteins (2006) 0.84
A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes. Cancer Res (2009) 0.83
NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer (2013) 0.81
Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int J Mol Med (2008) 0.80
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clin Cancer Res (2005) 0.76
In silico strategy for detection of target candidates for antibody therapy of solid tumors. Gene (2008) 0.75